Gitlitz B - Search Results

1

Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.

Tso CL, Zisman A, Pantuck A, Calilliw R, Hernandez JM, Paik S, Nguyen D, Gitlitz B, Shintaku PI, de Kernion J, Figlin R, Belldegrun A. Tso CL, et al. Among authors: gitlitz b. Cancer Res. 2001 Nov 1;61(21):7925-33. Cancer Res. 2001. PMID: 11691814

2

Immunologic approaches to the treatment of cancer.

Figlin RA, Gitlitz BJ, Belldegrun A. Figlin RA, et al. Among authors: gitlitz bj. Cancer Invest. 1995;13(3):339-40. doi: 10.3109/07357909509094469. Cancer Invest. 1995. PMID: 7743386 No abstract available.

3

Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.

Franklin JR, Figlin R, Rauch J, Gitlitz B, Belldegrun A. Franklin JR, et al. Among authors: gitlitz b. Semin Urol Oncol. 1996 Nov;14(4):230-6. Semin Urol Oncol. 1996. PMID: 8946623

4

Immunotherapy and gene therapy.

Gitlitz BJ, Belldegrun A, Figlin RA. Gitlitz BJ, et al. Semin Urol Oncol. 1996 Nov;14(4):237-43. Semin Urol Oncol. 1996. PMID: 8946624 Review.

5

Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor.

Figlin RA, Pierce WC, Kaboo R, Tso CL, Moldawer N, Gitlitz B, deKernion J, Belldegrun A. Figlin RA, et al. Among authors: gitlitz b. J Urol. 1997 Sep;158(3 Pt 1):740-5. doi: 10.1097/00005392-199709000-00012. J Urol. 1997. PMID: 9258071 Clinical Trial.

6

Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.

Figlin R, Gitlitz B, Franklin J, Dorey F, Moldawer N, Rausch J, deKernion J, Belldegrun A. Figlin R, et al. Among authors: gitlitz b. Cancer J Sci Am. 1997 Dec;3 Suppl 1:S92-7. Cancer J Sci Am. 1997. PMID: 9457402 Clinical Trial.

7

Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma.

Mulders P, Tso CL, Pang S, Kaboo R, McBride WH, Hinkel A, Gitlitz B, Dannull J, Figlin R, Belldegrun A. Mulders P, et al. Among authors: gitlitz b. J Immunother. 1998 May;21(3):170-80. doi: 10.1097/00002371-199805000-00002. J Immunother. 1998. PMID: 9610908

8

Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines.

Mulders P, Tso CL, Gitlitz B, Kaboo R, Hinkel A, Frand S, Kiertscher S, Roth MD, deKernion J, Figlin R, Belldegrun A. Mulders P, et al. Among authors: gitlitz b. Clin Cancer Res. 1999 Feb;5(2):445-54. Clin Cancer Res. 1999. PMID: 10037196

9

Immunomodulatory dendritic cells generated from nonfractionated bulk peripheral blood mononuclear cell cultures induce growth of cytotoxic T cells against renal cell carcinoma.

Hinkel A, Tso CL, Gitlitz BJ, Neagos N, Schmid I, Paik SH, deKernion J, Figlin R, Belldegrun A. Hinkel A, et al. Among authors: gitlitz bj. J Immunother. 2000 Jan;23(1):83-93. doi: 10.1097/00002371-200001000-00011. J Immunother. 2000. PMID: 10687141

10

Granulocyte macrophage colony-stimulating factor and interleukin 4 enhance the number and antigen-presenting activity of circulating CD14+ and CD83+ cells in cancer patients.

Roth MD, Gitlitz BJ, Kiertscher SM, Park AN, Mendenhall M, Moldawer N, Figlin RA. Roth MD, et al. Among authors: gitlitz bj. Cancer Res. 2000 Apr 1;60(7):1934-41. Cancer Res. 2000. PMID: 10766183 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

83 results

Search Page

Filters